Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ignacio Pérez-Valero

Showing results (1-10 of 40) with videos related to

Pageof 4
Sort By:
Enfermedades Infecciosas Y Microbiologia Clinica|July 3, 2009
[Prognostic factors of virological response in patients treated with lopinavir/ritonavir monotherapy]Ignacio Pérez Valero
Current Opinion in Infectious Diseases|December 15, 2010
Protease inhibitor monotherapyIgnacio Pérez-Valero, Jose R Arribas
AIDS Reviews|June 3, 2015
Rezolsta® (Darunavir/Cobicistat): First Boosted Protease Inhibitor Co-formulated with CobicistatAdrián Curran, Ignacio Pérez-Valero, José Moltó
HIV Medicine|March 16, 2022
Perception of HIV physicians in Spain towards diagnosis and management of neuropsychiatric comorbidities in people with HIVIgnacio Pérez-Valero, Jordi Blanch, Esteban Martínez
AIDS Reviews|June 18, 2014
Central nervous system penetration and effectiveness of darunavir/ritonavir monotherapyIgnacio Pérez Valero, Alicia González-Baeza, María Luisa Montes Ramírez
Expert Review of Anti-Infective Therapy|April 19, 2023
Real-world discontinuations due to neuropsychiatric symptoms in people living with HIV treated with second-generation integrase inhibitors: a systematic reviewIgnacio Pérez-Valero, Diana Corona, Natalia Martínez, et al.
Journal of the International AIDS Society|November 14, 2014
Cerebral volumes, neuronal integrity and brain inflammation measured by MRI in patients receiving PI monotherapy or triple therapyIgnacio Pérez Valero, Alicia Gonzalez Baeza, Juan Antonio Hernandez-Tamames, et al.
Open Forum Infectious Diseases|March 24, 2016
Long-Term Control of Human Immunodeficiency Virus-1 Replication Despite Extensive Resistance to Current Antiretroviral Regimens: Clonal Analysis of Resistance Mutations in Proviral Deoxyribonucleic AcidNatalia Stella-Ascariz, Rocio Montejano, María Martin-Vicente, et al.
The Journal of Antimicrobial Chemotherapy|March 18, 2008
Long-term (4 years) efficacy of lopinavir/ritonavir monotherapy for maintenance of HIV suppressionFederico Pulido, Rafael Delgado, Ignacio Pérez-Valero, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|September 9, 2014
A comparative study of neurocognitively impaired patients receiving protease inhibitor monotherapy or triple-drug antiretroviral therapyMiriam Estébanez, Natalia Stella-Ascariz, Jesús Mingorance, et al.
Pageof 4

Showing results (1-10 of 40) with videos related to

Sort By:
Pageof 4
Enfermedades Infecciosas Y Microbiologia Clinica|July 3, 2009
[Prognostic factors of virological response in patients treated with lopinavir/ritonavir monotherapy]Ignacio Pérez Valero
Current Opinion in Infectious Diseases|December 15, 2010
Protease inhibitor monotherapyIgnacio Pérez-Valero, Jose R Arribas
AIDS Reviews|June 3, 2015
Rezolsta® (Darunavir/Cobicistat): First Boosted Protease Inhibitor Co-formulated with CobicistatAdrián Curran, Ignacio Pérez-Valero, José Moltó
HIV Medicine|March 16, 2022
Perception of HIV physicians in Spain towards diagnosis and management of neuropsychiatric comorbidities in people with HIVIgnacio Pérez-Valero, Jordi Blanch, Esteban Martínez
AIDS Reviews|June 18, 2014
Central nervous system penetration and effectiveness of darunavir/ritonavir monotherapyIgnacio Pérez Valero, Alicia González-Baeza, María Luisa Montes Ramírez
Expert Review of Anti-Infective Therapy|April 19, 2023
Real-world discontinuations due to neuropsychiatric symptoms in people living with HIV treated with second-generation integrase inhibitors: a systematic reviewIgnacio Pérez-Valero, Diana Corona, Natalia Martínez, et al.
Journal of the International AIDS Society|November 14, 2014
Cerebral volumes, neuronal integrity and brain inflammation measured by MRI in patients receiving PI monotherapy or triple therapyIgnacio Pérez Valero, Alicia Gonzalez Baeza, Juan Antonio Hernandez-Tamames, et al.
Open Forum Infectious Diseases|March 24, 2016
Long-Term Control of Human Immunodeficiency Virus-1 Replication Despite Extensive Resistance to Current Antiretroviral Regimens: Clonal Analysis of Resistance Mutations in Proviral Deoxyribonucleic AcidNatalia Stella-Ascariz, Rocio Montejano, María Martin-Vicente, et al.
The Journal of Antimicrobial Chemotherapy|March 18, 2008
Long-term (4 years) efficacy of lopinavir/ritonavir monotherapy for maintenance of HIV suppressionFederico Pulido, Rafael Delgado, Ignacio Pérez-Valero, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|September 9, 2014
A comparative study of neurocognitively impaired patients receiving protease inhibitor monotherapy or triple-drug antiretroviral therapyMiriam Estébanez, Natalia Stella-Ascariz, Jesús Mingorance, et al.
Pageof 4